<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489761</url>
  </required_header>
  <id_info>
    <org_study_id>CVRF2011-9</org_study_id>
    <nct_id>NCT01489761</nct_id>
  </id_info>
  <brief_title>LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)</brief_title>
  <official_title>Percutaneous Treatment of Very LONG Native Coronary Lesions With Drug-Eluting Stent-VI: Everolimus-eluting Versus Zotarolimus-Eluting Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, study to compare the efficacy of zotarolimus-eluting
      stent (Resolute Integrity or Resolute Onyx stent) or everolimus-eluting stent (Xience Prime
      or Xience Xpedition or Xience Alpine stent) for very long coronary lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following angiography, patients with significant diameter stenosis &gt; 50% and lesion length (&gt;
      50mm) requiring at least 2 multiple long-stent placement by visual estimation and eligible
      for LONG-DES VI trial inclusion and exclusion criteria will be randomized 1:1 to
      zotarolimus-eluting stent (Resolute Integrity or Resolute Onyx stent) or everolimus-eluting
      stent (Xience Prime or Xience Xpedition or Xience Alpine stent) by the stratified
      randomization method.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late luminal loss at 13 month follow-up</measure>
    <time_frame>13 month post stenting</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. All Death</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Cardiac death</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Myocardial infarction (MI)</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Composite of death or MI</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Composite of cardiac death or MI</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. Target vessel revascularization (ischemia-driven and clinically-driven)</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7. Target lesion revascularization (ischemia-driven and clinically-driven)</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8. Target-vessel failure (death from any cause, myocardial infarction, and ischemic-driven target-vessel revascularization)</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9. Stent thrombosis (ARC criteria)</measure>
    <time_frame>12 month clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10. In-stent late loss</measure>
    <time_frame>13 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11. In-stent and in-segment restenosis</measure>
    <time_frame>13 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12. Angiographic pattern of restenosis</measure>
    <time_frame>13 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13. Volume of intimal hyperplasia</measure>
    <time_frame>13 month IVUS follow-up</time_frame>
    <description>sub-study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>14. Incidence of late stent malapposition</measure>
    <time_frame>13 month IVUS follow-up</time_frame>
    <description>sub-study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>15. Procedural success defined as achievement of a final diameter stenosis of &lt;30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion during the hospital stay</measure>
    <time_frame>2-3 days post stenting</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>zotarolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resolute Integrity or Resolute Onyx stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>everolimus-eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xience Prime or Xience Xpedition or Xience Alpine stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>percutaneous coronary intervention</intervention_name>
    <description>drug eluting stent implantation</description>
    <arm_group_label>zotarolimus-eluting stent</arm_group_label>
    <arm_group_label>everolimus-eluting stent</arm_group_label>
    <other_name>Resolute Integrity or Resolute Onyx stent</other_name>
    <other_name>Xience Prime or Xience Xpedition or Xience Alpine stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than 20 years

          -  Significant native coronary artery stenosis (&gt; 50% by visual estimate) with lesion
             length of more than 50mm, which requires at least 2 multiple long stent placement
             without intervening normal segment

          -  Patients with silent ischemia, stable or unstable angina pectoris, and
             Non-ST-elevation myocardial infarction (NSTEMI)

          -  The patient or guardian agrees to the study protocol and the schedule of clinical and
             angiographic follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site

        Exclusion Criteria:

          -  Any contraindication to any of the following medications: aspirin, heparin,
             clopidogrel, stainless steel, contrast agents, zotarolimus, or everolimus

          -  An elective surgical procedure is planned that would necessitate interruption of
             antiplatelet drugs during the first 6 months post enrollment

          -  Acute ST-segment-elevation MI or cardiogenic shock

          -  Terminal illness with life expectancy &lt; 1 year

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period

          -  In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent
             segment) However, non-target vessel In-stent restenosis is permitted

          -  Patients with EF &lt; 30%

          -  Serum creatinine level &gt;=2.0mg/dL or dependence on dialysis

          -  Patients with left main stem stenosis (&gt; 50% visual estimate)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangwon National Univ. Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National university hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Service Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.carollo Hospital</name>
      <address>
        <city>Suncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>long lesions</keyword>
  <keyword>drug eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not a publicly funded trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

